Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion

Urogen Pharma (URGN) Financials

Urogen Pharma logo
$28.89 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$28.90 +0.01 (+0.03%)
As of 05/22/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Urogen Pharma

Annual Income Statements for Urogen Pharma

This table shows Urogen Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -154
Consolidated Net Income / (Loss)		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Net Income / (Loss) Continuing Operations		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Total Pre-Tax Income 		-13 -1.94 -20 -76 -105 -125 -109 -108 -98 -124 -153
Total Operating Income		 -12 0.80 -20 -77 -109 -127 -92 -79 -66 -97 -125
Total Gross Profit		 0.00 18 7.56 -0.68 0.02 11 43 57 73 82 97
Total Revenue		 0.00 18 8.16 1.13 0.02 12 48 64 83 90 110
Operating Revenue		 0.00 18 8.16 1.13 0.02 12 48 64 83 90 110
Total Cost of Revenue		 0.00 0.03 0.60 1.80 0.00 1.01 5.16 7.65 9.36 8.88 12
Operating Cost of Revenue		 0.00 0.03 0.60 1.80 0.00 1.01 5.16 7.65 9.36 8.88 12
Total Operating Expenses		 12 17 28 77 109 138 135 136 139 178 222
Selling, General & Admin Expense		 1.90 6.42 8.81 40 60 90 88 83 93 121 155
Research & Development Expense		 11 10 19 37 49 47 48 53 46 57 67
Total Other Income / (Expense), net		 -0.28 -2.74 -0.03 1.65 4.33 1.63 -17 -29 -33 -27 -29
Interest Expense		 - - - - - - 0.00 8.44 15 13 15
Interest & Investment Income		 - - -0.03 1.65 4.33 1.63 0.21 1.01 3.48 8.67 5.30
Other Income / (Expense), net		 -0.28 -2.74 - - - 0.00 -17 -22 -22 -23 -19
Income Tax Expense		 0.00 - 0.02 0.13 0.00 3.37 1.45 1.76 3.92 2.83 0.08
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - 0.00 0.00 - 0.01 - 0.08 -0.12 -0.04 0.04
Basic Earnings per Share		 ($5.88) ($1.91) ($2.14) ($4.80) ($5.12) ($5.90) ($4.96) ($4.81) ($3.55) ($2.96) ($3.19)
Weighted Average Basic Shares Outstanding		 2.30M 2.31M 9.72M 15.75M 20.53M 21.78M 22.35M 22.81M 28.83M 42.88M 48.12M
Weighted Average Diluted Shares Outstanding		 2.30M 2.31M 9.72M 15.75M 20.53M 21.78M 22.35M 23.44M 34.12M 46.09M 48.68M
Weighted Average Basic & Diluted Shares Outstanding		 2.30M 2.31M 9.72M 15.75M 20.53M 21.78M 22.35M 23.44M 34.12M 46.09M 48.68M

Quarterly Income Statements for Urogen Pharma

This table shows Urogen Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -22 -26 -32 -33 -23 -38 -44 -50 -33 -26 -24
Consolidated Net Income / (Loss)		 -22 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24
Net Income / (Loss) Continuing Operations		 -22 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24
Total Pre-Tax Income 		-22 -22 -32 -33 -24 -35 -43 -49 -34 -27 -28
Total Operating Income		 -14 -15 -26 -26 -18 -28 -37 -41 -27 -19 -20
Total Gross Profit		 18 21 17 20 23 22 18 21 24 35 47
Total Revenue		 21 24 19 22 25 25 20 24 27 38 51
Operating Revenue		 21 24 19 22 25 25 20 24 27 38 51
Total Cost of Revenue		 2.37 2.29 1.73 2.23 2.45 2.47 2.33 3.55 3.28 3.29 4.14
Operating Cost of Revenue		 2.37 2.29 1.73 2.23 2.45 2.47 2.33 3.55 3.28 3.29 4.14
Total Operating Expenses		 32 36 43 45 40 50 55 62 52 54 67
Selling, General & Admin Expense		 22 25 27 30 29 35 35 43 38 39 51
Research & Development Expense		 10 11 15 15 11 15 20 19 14 14 16
Total Other Income / (Expense), net		 -8.39 -7.55 -6.49 -7.53 -6.04 -7.21 -6.54 -7.48 -7.02 -7.52 -8.08
Interest Expense		 3.82 3.59 2.45 3.46 2.72 3.89 4.07 4.13 3.37 3.77 4.19
Interest & Investment Income		 0.91 1.54 1.62 1.71 2.60 2.75 2.11 1.30 0.98 0.90 0.61
Other Income / (Expense), net		 -5.48 -5.51 -5.66 -5.77 -5.92 -6.06 -4.58 -4.64 -4.62 -4.66 -4.51
Income Tax Expense		 -0.01 3.85 0.05 0.04 0.09 2.65 0.39 1.02 -1.05 -0.28 -4.77
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.02 -0.15 0.05 -0.01 -0.27 0.18 0.04 0.01 -0.02 0.00 0.01
Basic Earnings per Share		 ($0.68) ($0.54) ($0.87) ($0.82) ($0.51) ($0.53) ($0.92) ($1.05) ($0.69) ($0.53) ($0.47)
Weighted Average Basic Shares Outstanding		 32.30M 28.83M 37.06M 40.50M 46.78M 42.88M 47.42M 47.74M 48.06M 48.12M 50.18M
Weighted Average Diluted Shares Outstanding		 30.87M 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M
Weighted Average Basic & Diluted Shares Outstanding		 30.87M 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M

Annual Cash Flow Statements for Urogen Pharma

This table details how cash moves in and out of Urogen Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 14 3.46 16 64 -51 3.88 -8.50 11 40 77 -61
Net Cash From Operating Activities		 -7.18 4.19 -9.57 -37 -71 -106 -85 -88 -76 -97 -162
Net Cash From Continuing Operating Activities		 -7.18 4.19 -9.57 -37 -71 -106 -85 -88 -76 -97 -162
Net Income / (Loss) Continuing Operations		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Consolidated Net Income / (Loss)		 -13 -1.94 -20 -76 -105 -128 -111 -110 -102 -127 -153
Depreciation Expense		 0.11 0.21 0.21 0.42 0.30 0.42 0.83 0.92 0.80 0.33 0.31
Amortization Expense		 - - 0.00 0.00 0.46 0.44 1.42 2.15 -0.02 -3.34 0.71
Non-Cash Adjustments To Reconcile Net Income		 4.79 4.71 6.47 31 29 28 37 24 21 27 18
Changes in Operating Assets and Liabilities, net		 0.61 1.21 3.76 7.16 4.32 -6.37 -13 -5.18 4.32 5.92 -28
Net Cash From Investing Activities		 -0.30 -0.72 -36 35 -146 93 4.07 1.06 -0.95 -21 62
Net Cash From Continuing Investing Activities		 -0.30 -0.72 -36 35 -146 93 4.07 1.06 -0.95 -21 62
Purchase of Property, Plant & Equipment		 -0.30 -0.70 -0.27 -0.56 -0.33 -1.22 -0.75 -0.25 -0.19 -0.30 -0.29
Purchase of Investments		 0.00 - -36 -0.05 -198 -30 -52 -63 -50 -128 -77
Sale and/or Maturity of Investments		 - - 0.00 36 53 124 57 64 49 108 139
Net Cash From Financing Activities		 22 -0.01 62 66 165 17 72 97 117 195 40
Net Cash From Continuing Financing Activities		 22 -0.01 62 66 165 17 72 97 117 195 40
Issuance of Debt		 - - 0.04 - - - 0.00 96 0.00 24 0.00
Issuance of Common Equity		 0.00 - 61 64 162 16 - 0.00 116 170 40
Other Financing Activities, net		 0.00 0.57 0.79 2.40 3.66 0.74 72 1.51 0.87 0.32 0.12

Quarterly Cash Flow Statements for Urogen Pharma

This table details how cash moves in and out of Urogen Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 99 -24 36 89 -95 47 -68 -11 -2.60 21 -0.80
Net Cash From Operating Activities		 -17 -13 -32 -24 -28 -14 -42 -40 -42 -38 -45
Net Cash From Continuing Operating Activities		 -17 -13 -32 -24 -28 -14 -42 -40 -42 -38 -45
Net Income / (Loss) Continuing Operations		 -22 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24
Consolidated Net Income / (Loss)		 -22 -26 -32 -33 -24 -38 -44 -50 -33 -26 -24
Depreciation Expense		 0.19 0.19 0.12 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.08
Amortization Expense		 0.49 -1.05 -0.92 0.12 -1.47 -1.07 0.03 0.05 0.00 0.63 2.58
Non-Cash Adjustments To Reconcile Net Income		 4.69 6.17 5.11 7.20 6.56 9.37 3.57 3.40 3.87 6.37 5.63
Changes in Operating Assets and Liabilities, net		 -0.79 7.80 -3.76 2.27 -9.15 16 -1.85 6.59 -13 -19 -30
Net Cash From Investing Activities		 0.40 -11 14 12 -107 61 -26 28 31 28 -21
Net Cash From Continuing Investing Activities		 0.40 -11 14 12 -107 61 -26 28 31 28 -21
Purchase of Property, Plant & Equipment		 -0.10 -0.06 0.00 -0.08 -0.10 -0.12 -0.04 -0.14 -0.09 -0.02 -0.05
Purchase of Investments		 -11 -15 0.00 - -119 -9.23 -66 -1.79 -8.72 -0.54 -25
Sale and/or Maturity of Investments		 11 3.54 14 12 12 70 40 30 40 28 4.15
Net Cash From Financing Activities		 116 0.04 55 100 40 0.07 0.03 0.30 8.27 31 65
Net Cash From Continuing Financing Activities		 116 0.04 55 100 40 0.07 0.03 0.30 8.27 31 66
Issuance of Debt		 - - - - - - 0.00 - - - 65
Issuance of Common Equity		 116 - 55 100 15 - 0.00 -0.00 7.97 32 0.00
Other Financing Activities, net		 0.02 0.04 0.00 0.14 0.12 0.07 0.03 0.30 0.30 -0.51 0.18

Annual Balance Sheets for Urogen Pharma

This table presents Urogen Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 23 76 104 202 122 120 136 178 286 200
Total Current Assets		 22 74 102 149 116 114 129 169 276 186
Cash & Equivalents		 21 37 101 50 53 44 55 95 172 111
Restricted Cash		 0.10 0.20 0.25 0.52 1.23 1.23 0.81 0.82 1.08 1.35
Short-Term Investments		 0.00 36 0.00 97 49 45 45 42 65 9.71
Accounts Receivable		 0.08 - - 0.00 7.05 12 13 15 20 33
Inventories, net		 0.11 0.32 - 0.00 1.96 4.83 4.33 5.67 9.23 16
Prepaid Expenses		 0.40 0.96 0.67 1.03 3.36 7.48 11 10 8.85 15
Plant, Property, & Equipment, net		 0.74 0.81 0.95 0.98 2.05 1.97 1.30 0.69 0.66 0.64
Total Noncurrent Assets		 0.27 0.27 0.37 53 4.34 3.39 5.42 8.44 8.92 14
Long-Term Investments		 0.02 0.03 0.05 49 2.12 0.90 0.22 4.73 5.20 0.18
Noncurrent Note & Lease Receivables		 - - - - - - - - 3.13 8.46
Other Noncurrent Operating Assets		 0.25 0.24 0.32 4.00 2.22 2.49 5.19 3.71 0.59 5.16
Total Liabilities & Shareholders' Equity		 23 76 104 202 122 120 136 178 286 200
Total Liabilities		 6.75 7.04 13 22 26 111 225 244 295 306
Total Current Liabilities		 3.14 7.04 13 19 21 22 24 31 46 46
Accounts Payable		 1.88 4.44 8.54 11 10 12 12 17 27 28
Current Employee Benefit Liabilities		 0.69 1.95 4.93 6.71 9.55 6.95 8.26 11 11 14
Other Current Liabilities		 0.57 - 0.00 1.59 1.86 3.33 3.28 3.86 7.95 5.19
Total Noncurrent Liabilities		 3.61 0.00 0.00 2.60 4.21 89 201 212 249 260
Long-Term Debt		 - - - - - 0.00 98 99 122 122
Capital Lease Obligations		 - - - - - - - 0.84 1.65 6.12
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 0.00 2.72 2.84 3.02 3.19 3.79 3.90
Other Noncurrent Operating Liabilities		 3.61 - 0.00 2.60 1.50 86 101 110 121 127
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 16 69 90 180 96 8.41 -89 -65 -8.80 -105
Total Preferred & Common Equity		 16 69 90 180 96 8.41 -89 -65 -8.80 -105
Total Common Equity		 16 69 90 180 96 8.41 -89 -65 -8.80 -105
Common Stock		 44 116 213 408 453 476 488 614 797 854
Retained Earnings		 -27 -47 -123 -228 -357 -467 -577 -679 -806 -960
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.28 0.27 -0.03 -0.11 0.01 0.06 0.02

Quarterly Balance Sheets for Urogen Pharma

This table presents Urogen Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 128 113 95 194 201 282 302 248 209 185 254
Total Current Assets		 122 96 81 182 197 279 295 237 197 169 237
Cash & Equivalents		 29 37 20 119 131 220 125 104 93 90 110
Restricted Cash		 0.81 0.81 0.82 0.82 0.82 0.83 1.07 1.08 1.08 1.35 1.33
Short-Term Investments		 67 29 27 28 33 21 125 92 64 37 30
Accounts Receivable		 9.43 12 16 13 14 17 23 20 20 20 55
Inventories, net		 4.86 5.47 4.99 5.00 7.24 7.44 7.59 7.59 7.13 8.34 21
Prepaid Expenses		 11 12 13 16 10 12 14 13 12 12 20
Plant, Property, & Equipment, net		 1.52 1.10 0.91 0.82 0.57 0.58 0.61 0.63 0.69 0.70 0.62
Total Noncurrent Assets		 5.36 16 13 11 3.25 2.30 6.24 9.81 11 16 16
Long-Term Investments		 0.22 10 8.19 6.73 0.71 0.38 4.82 4.69 4.81 0.56 0.18
Noncurrent Note & Lease Receivables		 - - - - - - - 4.75 5.55 8.49 7.94
Other Noncurrent Operating Assets		 5.14 5.49 4.92 3.96 2.54 1.92 1.42 0.37 0.80 6.76 7.49
Total Liabilities & Shareholders' Equity		 128 113 95 194 201 282 302 248 209 185 254
Total Liabilities		 192 230 234 236 241 252 276 294 302 300 378
Total Current Liabilities		 19 25 27 26 26 34 33 42 48 42 51
Accounts Payable		 9.36 17 16 14 18 24 20 30 31 26 35
Current Employee Benefit Liabilities		 6.63 4.92 6.72 8.15 4.99 6.85 9.03 6.97 12 11 9.84
Other Current Liabilities		 3.02 3.19 3.64 3.55 3.20 3.62 4.07 4.71 4.94 4.96 5.45
Total Noncurrent Liabilities		 173 204 207 210 214 217 244 252 255 258 327
Long-Term Debt		 72 98 98 99 98 98 122 122 123 122 190
Capital Lease Obligations		 - - - - - - - 2.84 3.41 6.24 5.65
Noncurrent Deferred & Payable Income Tax Liabilities		 2.84 3.02 3.02 3.02 3.19 3.19 3.19 3.79 3.79 3.79 3.90
Other Noncurrent Operating Liabilities		 98 103 106 108 114 116 119 123 125 126 128
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - 0.00 - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -63 -117 -138 -42 -40 30 26 -46 -93 -115 -124
Total Preferred & Common Equity		 -63 -117 -138 -42 -40 30 26 -46 -93 -115 -124
Total Common Equity		 -63 -117 -138 -42 -40 30 26 -46 -93 -115 -124
Common Stock		 485 491 493 611 672 775 794 804 807 818 859
Retained Earnings		 -548 -607 -631 -653 -712 -745 -769 -850 -900 -933 -983
Accumulated Other Comprehensive Income / (Loss)		 -0.16 -0.05 -0.15 -0.13 -0.04 -0.03 0.24 0.01 0.01 0.02 0.01

Annual Metrics And Ratios for Urogen Pharma

This table displays calculated financial ratios and metrics derived from Urogen Pharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 46,808,892.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 46,808,892.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -3.28
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -8.69 0.56 -14 -54 -77 -89 -65 -55 -46 -68 -87
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -134.20% -59.12% -382.38%
Earnings before Interest and Taxes (EBIT)		 -13 -1.94 -20 -77 -109 -127 -110 -101 -87 -120 -143
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -1.73 -20 -77 -109 -126 -107 -98 -86 -123 -142
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 5.73 -14 -47 -72 -96 9.24 -45 -30 -48 -117
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -5.17 -4.71 -12 -16 -9.01 -83 -93 -108 -128 -99
Increase / (Decrease) in Invested Capital		 0.00 -5.17 0.46 -6.82 -4.55 7.07 -74 -9.97 -16 -20 29
Book Value per Share		 $0.00 $7.07 $7.05 $6.55 $8.59 $4.36 $0.38 ($3.87) ($2.11) ($0.21) ($2.25)
Tangible Book Value per Share		 $0.00 $7.07 $7.05 $6.55 $8.59 $4.36 $0.38 ($3.87) ($2.11) ($0.21) ($2.25)
Total Capital		 0.00 16 69 90 180 96 8.41 8.18 34 115 23
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 98 99 123 128
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 98 99 123 128
Net Debt		 0.00 -21 -73 -102 -196 -105 -91 -3.46 -43 -120 6.35
Capital Expenditures (CapEx)		 0.30 0.70 0.27 0.56 0.33 1.22 0.75 0.25 0.19 0.30 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.55 -5.76 -13 -18 -9.06 1.65 4.21 0.19 -7.58 18
Debt-free Net Working Capital (DFNWC)		 0.00 19 67 89 129 94 92 105 138 230 140
Net Working Capital (NWC)		 0.00 19 67 89 129 94 92 105 138 230 140
Net Nonoperating Expense (NNE)		 4.00 2.50 6.04 22 29 40 46 54 56 59 66
Net Nonoperating Obligations (NNO)		 0.00 -21 -73 -102 -196 -105 -91 -3.46 -43 -120 6.35
Total Depreciation and Amortization (D&A)		 0.11 0.21 0.21 0.42 0.75 0.86 2.25 3.07 0.78 -3.01 1.01
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.91) $0.00 ($4.80) ($5.12) ($5.90) ($4.96) ($4.81) ($3.55) ($2.96) ($3.19)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.31M 0.00 20.48M 21.15M 22.27M 22.67M 22.81M 28.83M 42.88M 48.12M
Adjusted Diluted Earnings per Share		 $0.00 ($1.91) $0.00 ($4.80) ($5.12) ($5.90) ($4.96) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.31M 0.00 20.48M 21.15M 22.27M 22.67M 23.44M 34.12M 46.09M 48.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.91) $0.00 ($4.80) ($5.12) ($5.90) ($4.96) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 2.31M 0.00 15.75M 20.53M 21.78M 22.35M 23.44M 34.12M 46.09M 48.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.69 0.56 -14 -54 -77 -89 -65 -55 -46 -68 -87
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Urogen Pharma

This table displays calculated financial ratios and metrics derived from Urogen Pharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 46,808,892.00 48,682,280.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 46,808,892.00 48,682,280.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.56 -0.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 29.54% 30.06% 9.24% 3.35% 20.87% 4.40% 7.84% 10.83% 9.04% - 151.60%
EBITDA Growth		 17.04% 14.89% -20.19% -55.18% -35.85% -65.58% -28.60% -46.26% -28.42% - 46.58%
EBIT Growth		 17.14% 20.70% -15.15% -52.52% -23.61% -67.65% -32.16% -45.81% -36.43% - 40.31%
NOPAT Growth		 25.36% 27.97% -16.76% -67.98% -29.96% -89.32% -43.41% -60.41% -56.09% - 45.11%
Net Income Growth		 15.30% 9.88% -6.86% -38.39% -8.20% -44.19% -35.80% -49.51% -40.87% - 46.23%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Cash Flow Growth		 1.78% 40.25% -22.97% -17.14% -59.92% -4.79% -32.42% -67.70% -52.80% - -7.83%
Free Cash Flow Firm Growth		 114.05% 225.08% -0.84% -115.17% -493.74% -87.10% -126.33% -3,265.84% -359.54% - -516.05%
Invested Capital Growth		 -11.41% -16.71% -13.97% -18.36% -9.95% -18.50% -13.92% -14.14% -7.16% - 42.47%
Revenue Q/Q Growth		 -1.36% 12.84% -20.18% 16.33% 15.36% -2.54% -17.55% 19.56% 13.49% - 34.68%
EBITDA Q/Q Growth		 9.63% -14.60% -60.41% 2.39% 20.89% -39.69% -19.22% -11.02% 30.54% - 4.12%
EBIT Q/Q Growth		 8.43% -5.98% -56.11% -0.68% 25.79% -43.74% -23.06% -11.07% 30.56% - -4.20%
NOPAT Q/Q Growth		 12.24% -8.21% -76.19% -0.38% 32.10% -57.64% -33.47% -12.28% 33.93% - -6.01%
Net Income Q/Q Growth		 9.35% -18.91% -24.10% -3.46% 29.13% -58.46% -16.88% -13.91% 33.23% - 10.58%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Cash Flow Q/Q Growth		 14.67% 24.87% -144.19% 25.17% -16.49% 50.77% -208.57% 5.23% -6.14% - -18.24%
Free Cash Flow Firm Q/Q Growth		 -74.96% 737.19% -177.84% 91.98% -549.88% 127.43% -1,684.06% -19.21% 11.27% - -55.98%
Invested Capital Q/Q Growth		 -2.07% -10.05% 0.97% -5.58% 5.18% -18.60% 4.06% -5.79% 10.98% - 28.52%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.65% 90.28% 90.80% 89.80% 90.27% 89.94% 88.50% 85.34% 88.07% - 91.88%
EBITDA Margin		 -87.76% -89.13% -171.41% -143.83% -98.64% -141.36% -204.40% -189.81% -116.17% - -43.40%
Operating Margin		 -64.74% -62.09% -137.05% -118.27% -69.61% -112.59% -182.26% -171.17% -99.65% - -39.76%
EBIT Margin		 -91.02% -85.48% -167.19% -144.69% -93.08% -137.27% -204.88% -190.34% -116.47% - -48.61%
Profit (Net Income) Margin		 -104.93% -110.57% -171.91% -152.89% -93.93% -152.71% -216.47% -206.24% -121.34% - -46.26%
Tax Burden Percent		 99.96% 117.39% 100.17% 100.11% 100.39% 107.60% 100.90% 102.07% 96.94% - 83.17%
Interest Burden Percent		 115.33% 110.18% 102.65% 105.55% 100.52% 103.39% 104.71% 106.15% 107.48% - 114.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 199.65% 132.29% 133.15% 210.11% 1,400.39% 342.83% 319.73% 491.48% 366.31% - 156.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 -43.67% -45.05% -89.91% -65.22% -33.57% -53.49% -83.99% -73.13% -46.16% - -27.24%
Return on Assets (ROA)		 -50.34% -58.26% -92.45% -68.91% -33.87% -59.50% -88.74% -79.24% -48.10% - -25.93%
Return on Common Equity (ROCE)		 199.65% 132.29% 133.15% 210.11% 1,400.39% 342.83% 319.73% 491.48% 366.31% - 156.08%
Return on Equity Simple (ROE_SIMPLE)		 250.27% 0.00% 259.92% -374.69% -452.20% 0.00% 297.97% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.45 -10 -18 -18 -12 -19 -26 -29 -19 -13 -14
NOPAT Margin		 -45.32% -43.46% -95.94% -82.79% -48.73% -78.81% -127.58% -119.82% -69.76% - -27.83%
Net Nonoperating Expense Percent (NNEP)		 -30.49% -67.79% -61.63% -29.89% -11.98% -22.31% -24.88% -23.07% -21.11% - -80.57%
Return On Investment Capital (ROIC_SIMPLE)		 - -29.92% - - - -16.90% -32.92% -89.15% -148.10% -58.54% -20.00%
Cost of Revenue to Revenue		 11.35% 9.72% 9.20% 10.20% 9.73% 10.06% 11.50% 14.66% 11.93% - 8.12%
SG&A Expenses to Revenue		 104.33% 104.34% 145.35% 137.57% 114.83% 141.90% 172.64% 178.40% 136.75% - 101.03%
R&D to Revenue		 49.06% 48.03% 82.50% 70.50% 45.05% 60.63% 98.11% 78.11% 50.97% - 30.61%
Operating Expenses to Revenue		 153.39% 152.37% 227.85% 208.06% 159.88% 202.53% 270.75% 256.51% 187.72% - 131.64%
Earnings before Interest and Taxes (EBIT)		 -19 -20 -31 -32 -23 -34 -41 -46 -32 -24 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -21 -32 -31 -25 -35 -41 -46 -32 -23 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 20.00 20.96 0.00 0.00 0.00 0.00 - 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 20.00 20.96 0.00 0.00 0.00 0.00 - 0.00
Price to Revenue (P/Rev)		 5.49 5.60 6.07 7.13 5.99 4.97 5.55 6.70 9.56 - 6.23
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 4.76 5.08 5.27 5.43 4.49 3.65 4.71 6.31 9.56 - 6.61
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.35 -1.52 -2.43 3.23 4.77 -14.02 -2.69 -1.35 -1.11 - -1.57
Long-Term Debt to Equity		 -2.35 -1.52 -2.43 3.23 4.77 -14.02 -2.69 -1.35 -1.11 - -1.57
Financial Leverage		 0.77 0.30 0.30 0.95 11.54 2.20 1.67 2.88 1.49 - 0.14
Leverage Ratio		 -3.06 -2.03 -2.00 -3.49 -30.08 -6.27 -5.18 -7.78 -5.42 - -2.94
Compound Leverage Factor		 -3.53 -2.24 -2.05 -3.68 -30.23 -6.48 -5.42 -8.26 -5.82 - -3.36
Debt to Total Capital		 174.29% 290.77% 169.85% 76.34% 82.67% 107.68% 159.19% 386.91% 991.59% - 275.19%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 174.29% 290.77% 169.85% 76.34% 82.67% 107.68% 159.19% 386.91% 991.59% - 275.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 -74.29% -190.77% -69.85% 23.66% 17.33% -7.68% -59.19% -286.91% -891.59% - -175.19%
Debt to EBITDA		 -1.09 -1.15 -1.07 -0.96 -1.12 -1.00 -0.94 -0.86 -0.83 - -1.59
Net Debt to EBITDA		 0.63 0.50 0.75 1.42 1.23 0.97 0.58 0.25 0.00 - -0.43
Long-Term Debt to EBITDA		 -1.09 -1.15 -1.07 -0.96 -1.12 -1.00 -0.94 -0.86 -0.83 - -1.59
Debt to NOPAT		 -1.98 -2.17 -2.01 -1.75 -2.08 -1.82 -1.65 -1.46 -1.37 - -2.58
Net Debt to NOPAT		 1.13 0.94 1.40 2.59 2.28 1.77 1.02 0.43 0.01 - -0.71
Long-Term Debt to NOPAT		 -1.98 -2.17 -2.01 -1.75 -2.08 -1.82 -1.65 -1.46 -1.37 - -2.58
Altman Z-Score		 -2.60 -3.17 -2.77 -1.28 -1.32 -2.14 -3.00 -4.20 -4.45 - -2.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.06 5.42 7.47 8.15 9.00 6.01 5.65 4.14 3.99 - 4.69
Quick Ratio		 6.21 4.88 6.77 7.55 8.31 5.59 5.13 3.71 3.47 - 3.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.63 5.28 -4.77 -0.38 -2.48 0.68 -11 -13 -11 -43 -66
Operating Cash Flow to CapEx		 -17,299.00% -23,207.14% 0.00% -28,271.43% -28,816.67% -11,842.61% -95,509.09% -28,244.68% -48,586.21% - -83,918.52%
Free Cash Flow to Firm to Interest Expense		 0.17 1.47 -1.95 -0.11 -0.91 0.18 -2.65 -3.11 -3.38 - -15.89
Operating Cash Flow to Interest Expense		 -4.53 -3.62 -12.97 -6.86 -10.17 -3.50 -10.33 -9.64 -12.53 - -10.83
Operating Cash Flow Less CapEx to Interest Expense		 -4.56 -3.64 -12.97 -6.89 -10.20 -3.53 -10.34 -9.67 -12.56 - -10.84
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.48 0.53 0.54 0.45 0.36 0.39 0.41 0.38 0.40 - 0.56
Accounts Receivable Turnover		 6.94 5.88 6.33 5.16 5.01 5.06 5.44 5.09 4.54 - 3.74
Inventory Turnover		 1.89 1.87 1.39 1.39 1.38 1.19 1.28 1.48 1.46 - 1.00
Fixed Asset Turnover		 65.99 83.30 101.02 114.11 124.90 134.52 154.02 148.64 148.14 - 226.05
Accounts Payable Turnover		 0.80 0.65 0.50 0.43 0.52 0.40 0.39 0.39 0.51 - 0.43
Days Sales Outstanding (DSO)		 52.61 62.10 57.70 70.67 72.80 72.16 67.14 71.78 80.37 - 97.49
Days Inventory Outstanding (DIO)		 192.78 194.92 262.85 263.47 264.35 306.19 285.46 246.11 250.08 - 364.99
Days Payable Outstanding (DPO)		 458.09 563.84 729.83 851.18 708.68 903.54 933.00 924.26 719.67 - 840.66
Cash Conversion Cycle (CCC)		 -212.70 -306.81 -409.29 -517.04 -371.53 -525.19 -580.40 -606.36 -389.23 - -378.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -98 -108 -108 -114 -108 -128 -123 -130 -116 -99 -71
Invested Capital Turnover		 -0.83 -0.82 -0.83 -0.81 -0.86 -0.76 -0.79 -0.77 -0.86 - -1.45
Increase / (Decrease) in Invested Capital		 -10 -16 -13 -18 -9.80 -20 -15 -16 -7.75 29 52
Enterprise Value (EV)		 368 420 444 462 401 330 433 595 922 - 929
Market Capitalization		 424 463 512 606 535 449 510 632 923 - 875
Book Value per Share		 ($1.39) ($2.11) ($1.18) $0.84 $0.61 ($0.21) ($1.01) ($2.03) ($2.49) ($2.25) ($2.55)
Tangible Book Value per Share		 ($1.39) ($2.11) ($1.18) $0.84 $0.61 ($0.21) ($1.01) ($2.03) ($2.49) ($2.25) ($2.55)
Total Capital		 57 34 57 128 147 115 78 33 13 23 71
Total Debt		 99 99 98 98 122 123 125 126 128 128 195
Total Long-Term Debt		 99 99 98 98 122 123 125 126 128 128 195
Net Debt		 -56 -43 -68 -144 -134 -120 -77 -37 -0.59 6.35 53
Capital Expenditures (CapEx)		 0.10 0.06 0.00 0.08 0.10 0.12 0.04 0.14 0.09 0.02 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 8.10 0.19 5.55 2.84 12 -7.58 -1.79 -8.72 -2.08 18 45
Debt-free Net Working Capital (DFNWC)		 156 138 170 245 262 230 195 149 126 140 187
Net Working Capital (NWC)		 156 138 170 245 262 230 195 149 126 140 187
Net Nonoperating Expense (NNE)		 12 16 14 15 11 18 18 21 14 13 9.39
Net Nonoperating Obligations (NNO)		 -56 -43 -68 -144 -134 -120 -77 -37 -0.59 6.35 53
Total Depreciation and Amortization (D&A)		 0.68 -0.86 -0.79 0.19 -1.40 -1.01 0.10 0.13 0.08 0.70 2.65
Debt-free, Cash-free Net Working Capital to Revenue		 10.48% 0.22% 6.59% 3.34% 13.05% -8.38% -1.95% -9.25% -2.15% - 32.19%
Debt-free Net Working Capital to Revenue		 202.31% 166.81% 202.15% 287.90% 293.53% 254.64% 212.45% 158.45% 130.86% - 132.98%
Net Working Capital to Revenue		 202.31% 166.81% 202.15% 287.90% 293.53% 254.64% 212.45% 158.45% 130.86% - 132.98%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.68) ($0.54) ($0.97) ($0.91) ($0.55) ($0.53) ($0.92) ($1.05) ($0.69) ($0.53) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 32.30M 28.83M 33.38M 36.82M 43.10M 42.88M 47.42M 47.74M 48.06M 48.12M 50.18M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 30.87M 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.87M 34.12M 36.13M 42.11M 42.20M 46.09M 46.11M 46.26M 46.81M 48.68M 48.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.45 -10 -18 -18 -12 -19 -26 -29 -19 -13 -14
Normalized NOPAT Margin		 -45.32% -43.46% -95.94% -82.79% -48.73% -78.81% -127.58% -119.82% -69.76% - -27.83%
Pre Tax Income Margin		 -104.97% -94.19% -171.62% -152.71% -93.56% -141.92% -214.53% -202.04% -125.18% - -55.63%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.97 -5.61 -12.83 -9.13 -8.62 -8.66 -10.20 -11.15 -9.49 - -5.92
NOPAT to Interest Expense		 -2.48 -2.85 -7.36 -5.23 -4.51 -4.97 -6.35 -7.02 -5.68 - -3.39
EBIT Less CapEx to Interest Expense		 -5.00 -5.62 -12.83 -9.16 -8.66 -8.69 -10.21 -11.19 -9.52 - -5.93
NOPAT Less CapEx to Interest Expense		 -2.50 -2.87 -7.36 -5.25 -4.55 -5.00 -6.36 -7.06 -5.71 - -3.40
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, investor-focused trend snapshot of UroGen Pharma Ltd. (NASDAQ: URGN) using the company’s quarterly statements from the last four years. The focus is on revenue, profitability, cash flow, and balance-sheet dynamics that matter to investors.

  • Revenue growth trend: UROGEN’s quarterly revenue has trended higher over the period, rising from mid-teens millions in 2022 to roughly $37.8 million in Q4 2025, marking a multi-year expansion (e.g., about $16.6m in 2022 Q2, $24.6m in 2024 Q4, $37.8m in 2025 Q4).
  • Gross margin remains robust: Gross profit margins run around the 90% range in recent quarters (e.g., Q4 2025 gross profit of $34.55m on $37.84m revenue, implying a margin near 91%).
  • Non-operating cash inflows from asset sales: The company generated sizable cash from selling or maturing investments across several quarters (e.g., Q4 2025 roughly $28.3m; Q3 2025 about $40.2m; Q2 2025 around $30.3m; Q1 2025 about $40.4m), aiding liquidity even as operations burn cash.
  • Equity financing activity provides liquidity: Strategic equity issuances helped bolster liquidity in 2025, including notable common equity issuances (e.g., around $31.8m in Q4 2025 and similar levels in Q1 2025).
  • Debt level remains sizeable but roughly stable: Long-term debt sits around $122 million in recent balance sheets, indicating a persistent leverage burden without a clear, rapid deleveraging, which keeps debt-servicing risk a consideration.
  • Operating cash flow remains negative: Cash flow from continuing operating activities has been negative across recent quarters (e.g., Q4 2025 around -$38.3m; Q3 2025 around -$42.3m; Q2 2025 around -$39.8m; Q1 2025 around -$42.0m), signaling ongoing cash burn despite revenue growth and investment cash inflows.
  • Ongoing net losses: Net income remains negative across 2025, with substantial quarterly losses (e.g., Q2 2025 net loss about -$49.9m; Q3 2025 about -$33.3m; Q4 2025 about -$26.4m; Q1 2025 about -$43.8m).
  • Negative equity and elevated liabilities: The balance sheet shows negative total equity in recent periods (e.g., Q3 2025 equity around -$115.4m) with Total Liabilities well in excess of Total Assets (e.g., Q3 2025: Total Liabilities ~$300.5m vs. Total Assets ~$185.0m), highlighting solvency and leverage concerns.
05/25/26 10:41 PM ETAI Generated. May Contain Errors.

Urogen Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Urogen Pharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Urogen Pharma's net income appears to be on an upward trend, with a most recent value of -$153.49 million in 2025, rising from -$12.69 million in 2015. The previous period was -$126.87 million in 2024. See where experts think Urogen Pharma is headed by visiting Urogen Pharma's forecast page.

Urogen Pharma's total operating income in 2025 was -$124.86 million, based on the following breakdown:
  • Total Gross Profit: $97.34 million
  • Total Operating Expenses: $222.20 million

Over the last 10 years, Urogen Pharma's total revenue changed from $0.00 in 2015 to $109.79 million in 2025, a change of 10,978,800,000.0%.

Urogen Pharma's total liabilities were at $305.93 million at the end of 2025, a 3.9% increase from 2024, and a 4,433.0% increase since 2016.

In the past 9 years, Urogen Pharma's cash and equivalents has ranged from $21.36 million in 2016 to $171.99 million in 2024, and is currently $110.75 million as of their latest financial filing in 2025.

Over the last 10 years, Urogen Pharma's book value per share changed from 0.00 in 2015 to -2.25 in 2025, a change of -225.3%.


Related Companies

Financial statements for NASDAQ:URGN last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel